Patents (1374 Stem Cell Patents)

Class: Use (255)

Order by:
<< | < | 10 11 12 13 14 15 16 17 18 | > | >>


Methods for therapy of neurodegenerative disease of the brain

Patent Number: 6451306

This patent covers a method of treating a neurodegenerative condition through administration of neuronal stem cells into the cholinergic basal forebrain that have been transfected with nerve growth factor or a neurotropin. This patent uses the natural ability of neural stem cells to migrate to the place where they are needed, in order to deliver the protein that is produced from the gene...

Inventors: Tuszynski, Mark H. (La Jolla, CA); Gage, Fred (La Jolla, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Wednesday April 15th, 1998

Mesenchymal stem cells as immunosuppressants

Patent Number: 6797269

This patent covers mesenchymal stem cells that are treated with interferon gamma for suppression of an immune response. Mesenchymal stem cells are naturally immunosuppressive...it may be that the interferon gamma treatment is activating the expression of the immune suppressive enzyme 2,3-indolamine-dehydrogenase (IDO), which selectively depletes tryptophan, thus stopping T cell...

Inventors: Mosca, Joseph D. (Ellicott City, MD); McIntosh, Kevin R. (Ellicott City, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Friday April 3rd, 1998

Method for transplantation of hemopoietic stem cells

Patent Number: 6383481

This patent teaches that intraportal administration of bone marrow subsequent to myeloablation can be used as a therapy for the treatment of autoimmune disease. This approach may be useful since it "reprograms" the immune system, allowing for it to come back into homeostasis. The problem with this is that several severe toxicities are usually associated with transplantation of bone...

Inventors: Ikehara, Susumu (Osaka, JP); Inaba, Muneo (Kyoto, JP); Takeuchi, Kenji (Osaka, JP); Kushida, Taketoshi (Amagasaki, JP)
Assignee: Japan Immunoresearch Laboratories Co., Ltd. (Gunma-Ken, JP)
Date of First Priority Issue: Monday March 30th, 1998

Cell-based gene therapy

Patent Number: 6592864

When cells are administered into the lung, many times they get stuck there. This invention takes advantage of this and claims the use of various cells, including stem cells, as vectors for genes that are beneficial for lung function. I believe that this inventor actually performed clinical trials by administration of iNOS transfected fibroblasts into patients with pulmonary hypertension.

Inventor: Stewart, Duncan John (Toronto, Ontario, CA)
Assignee: None Stated
Date of First Priority Issue: Friday March 27th, 1998

Mesenchymal stem cells for prevention and treatment of immune responses in transplantation

Patent Number: 6875430

Xenotransplantation is limited primarily by antibody mediated rejection. Accordingly while this patent covers the use of mesenchymal stem cells for preventing xenograft rejection, the actual applicability of this patent seems unlikely since mesenchymal stem cells do not strongly protect against antibody mediated immune rejection in xenotransplantation.

Inventors: McIntosh, Kevin R. (Ellicott City, MD); Mosca, Joseph D. (Ellicott City, MD); Klyushnenkova, Elena (Baltimore, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Wednesday March 18th, 1998

Mesenchymal stem cells for prevention and treatment of immune responses in transplantation

Patent Number: 6368636

This patent teaches the use of mesenchymal stem cells for preventing allograft rejection through immune modulation. It is known that bone marrow cells can display a veto-like effect in that they are capable of inducing donor-specific tolerance. The bone marrow cells are one source of mesenchymal stem cells. In this patent purified mesenchymal stem cells are claimed not only for inducing...

Inventors: McIntosh, Kevin R. (Ellicott City, MD); Mosca, Joseph D. (Ellicott City, MD); Klyushnenkova, Elena N. (Baltimore, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Wednesday March 18th, 1998

Uses for non-autologous mesenchymal stem cells

Patent Number: 7029666

This patent teaches therapeutic uses of mesenchymal stem cells that are NOT MHC matched. Two specific uses seem to be covered: connective tissue regeneration, and muscle regeneration. The patent has two independent claims, the first covers a method of promoting muscle growth in a human by administration of non-MHC matched mesenchymal stem cells, whereas the second...

Inventors: Bruder, Scott P. (Waltham, MA); McIntosh, Kevin R. (Ellicott City, MD); Marshak, Daniel R. (Lutherville, MD); Mosca, Joseph D. (Ellicott City, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Friday March 13th, 1998

Uses for non-autologous mesenchymal stem cells

Patent Number: 6355239

This patent covers the use of mesenchymal stem cells that are either allogeneic or xenogeneic for the purposes of regeneration and/or enhancing hematopoietic graft function. Since mesenchymal stem cells are immunosuppressive (at least locally), the use of immunosuppressants can be avoided. This patent would be interesting to use with islet grafts for the treatment of diabetes. I mean, some...

Inventors: Bruder, Scott P. (Waltham, MA); McIntosh, Kevin R. (Ellicott City, MD); Marshak, Daniel R. (Lutherville, MD); Mosca, Joseph D. (Ellicott City, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Friday March 13th, 1998

Method of promoting production of living tissue equivalents

Patent Number: 6498138

This patent covers the use of angiotensinogen I and II and fragments thereof for promoting viability of tissues. This could be used form maintaining the viability of stem cells during organ storage.

Inventors: Rodgers, Kathleen E. (Long Beach, CA); DiZerega, Gere (Pasadena, CA)
Assignee: University of Southern California (Los Angeles, CA)
Date of First Priority Issue: Wednesday March 11th, 1998

Use of cytokines and mitogens to inhibit graft versus host disease

Patent Number: 7,381,563

Hematopoietic stem cell transplantation has saved hundreds of thousands of lives of patients with hematopoietic malignancies or some metabolic disorders.  Hematopoietic stem cell transplant involves administration of CD34 cells or unpurified mononuclear cells from either donor bone marrow, cord blood, or mobilized peripheral blood.  Since the "graft" in this type of...

Inventors: Horwitz; David A. (Santa Monica, CA)
Assignee: University of Southern California (Los Angeles, CA)
Date of First Priority Issue: Tuesday March 3rd, 1998

Order by:
<< | < | 10 11 12 13 14 15 16 17 18 | > | >>




Home | News | Patents | Products | Journal | Jobs | Search | RSS

About | Advisory Board | Newsletter | Advertise | Contact | Sitemap | Privacy Policy | Terms of Use

Copyright © 2006 - 2009 StemCellPatents.com - All rights reserved. - Toronto Web Design

StemCellPatents.com V2.03